The opportunity for each member of a NewCo to take on multiple responsibilities selects early for people ready to help a startup get its footing. We were no exception at Spero, when we started off with a $400k seed investment a little more than 6 years ago. Funds were tight to hire a controller and we were weeks away from a go/no go data point, so I put on my green visor and volunteered (fortunately briefly!) to do the company’s accounting. Thankfully, the science advanced, we raised funds, and I was thrilled to give that responsibility up to a great team. Sometimes, though, the choice to give up a responsibility is not that easy.
By Ankit Mahadevia, CEO and Founder of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC.
Read more.
Generation Bio is looking to move the field of gene therapy into the future, and thinks it has a manufacturing process in place that will allow enough scale for broad disease indications. Now, all it needs is a plant to put those large-scale ambitions into action.
Read more.
Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4) in 2011 and the seminal initial efficacy disclosure on nivolumab (anti-PD1) in 2012 (Topalian et al NEJM), we can reflect on how I-O has literally changed the lives of tens of thousands of cancer patients and their families.
By Tim Reilly & Jonathan Montagu, CDO and CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC
Read more.
Atlas Venture, a leading early stage venture capital firm, announced today that Jodie Morrison is joining the firm as a venture partner. Jodie will work with the Atlas team to build transformative new biotech companies.
Read more.
Holy cow, have we seen the rain lately – both downpours outside and a downpour of SPAC activity.
By Sam Truex, Venture Partner at Atlas Venture, as part of the From The Trenches feature of LifeSciVC.
Read more.